Ginkgo Bioworks Holdings, Inc. vs. Kymera Therapeutics, Inc. Common Stock
DNA
Ginkgo Bioworks Holdings, Inc.
$7.40 +6.32%
VS KYMRKymera Therapeutics, Inc. Common Stock
$119.80 -1.40%
Ginkgo Bioworks Holdings, Inc. (DNA) comes out ahead, leading on 5 of 8 compared factors.
Size & Scale
| DNA | KYMR | |
|---|---|---|
| Market Cap | $468.69 million | $10.10 billion |
| Revenue (TTM) | $111.86 million | $105.00 million |
| Net Income (TTM) | $-290,803,000 | $-299,601,000 |
DNA leads on 2 of 3 size & scale factors.
Valuation
| DNA | KYMR | |
|---|---|---|
| Price / Book | 1.12 | 6.69 |
| Price / Sales | 4.19 | 96.22 |
DNA leads on 2 of 2 valuation factors.
Profitability
| DNA | KYMR | |
|---|---|---|
| Net Margin | -259.96% | -285.34% |
| Return on Equity | -69.19% | -19.85% |
DNA and KYMR split the profitability factors evenly.
Risk & Sentiment
| DNA | KYMR | |
|---|---|---|
| Short Interest | 18.73% | 0.24% |
KYMR leads on 1 of 1 risk & sentiment factors.
Dig deeper: DNA overview, DNA financials, KYMR overview, KYMR financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.